Cambridge Investment Research Advisors, Inc. Madrigal Pharmaceuticals, Inc. Transaction History
Cambridge Investment Research Advisors, Inc.
- $29.4 Billion
- Q3 2024
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 1,429 shares of MDGL stock, worth $475,456. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,429
Previous 2,329
38.64%
Holding current value
$475,456
Previous $652,000
53.53%
% of portfolio
0.0%
Previous 0.0%
Shares
28 transactions
Others Institutions Holding MDGL
# of Institutions
303Shares Held
22MCall Options Held
819KPut Options Held
644K-
Janus Henderson Group PLC London, X02.48MShares$825 Million0.28% of portfolio
-
John Paulson Paulson & Co. Inc. | New York, Ny2.04MShares$679 Million29.57% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.03MShares$675 Million6.48% of portfolio
-
Rtw Investments, LP New York, NY1.99MShares$663 Million6.74% of portfolio
-
Baker Bros. Advisors LP New York, NY1.97MShares$657 Million4.49% of portfolio
About MADRIGAL PHARMACEUTICALS, INC.
- Ticker MDGL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 17,103,400
- Market Cap $5.69B
- Description
- Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...